Publication details
Postavení fixní dvojkombinace Amesos v léčbě hypertenze
| Title in English | Fixed position triple Amesos in treating hypertension |
|---|---|
| Authors | |
| Year of publication | 2015 |
| Type | Article in Periodical |
| Magazine / Source | Acta medicinae |
| MU Faculty or unit | |
| Citation | |
| Field | Other specializations of internal medicine |
| Keywords | fixed-combination therapy; ACE inhibitors; calcium channel blockers |
| Description | Fixed-combination therapy represents definitely the right way in the current treatment of hypertension since there are no newly developed antihypertensive drugs suitable for the clinical use nowadays. Combination therapy is more efficient than increasing of doses of a single drug and by using combination therapy we reach hypertension control faster and more efficiently. Moreover, the adverse events occur in much lesser extent because we are using lower doses of individual drugs. Nowadays, the most commonly used double-combinations are those that were tested in the large prospective studies and they include the combination of angiotensin-converting enzyme inhibitors (ACEi) and calcium channel blockers (CCB); as tested in ASCOT and ACCOMPLISH studies, both performed in high cardiovascular risk cohorts. Double-combination of ACEi and diuretics also remains the classical double-combination that is especially useful in the treatment of hypertension in the elderly (HYVET study), in the prevention of ischemic stroke (PROGRESS study) and also in the treatment of diabetic patients where indapamid should be the diuretics of choice (ADVANCE study). In patients with hypertension and left ventricular hypertrophy, combination of sartan and diuretics was successful as shown in the LIFE study. Last but not the least, combination of ACEi and CBB is reasonable from the pathophysiological reasons, since both blockers of renin-angiotensin system (RAS) and CBB are metabolically neutral compared to the most of the diuretics and betablockers, which is especially important in individuals at high cardiometabolic risk. |